Key result
CRT yields greater benefit in shorter patients, with height and QRS duration independently predicting major events.
Why the study?
Does cardiac resynchronization therapy reduce all-cause mortality and heart failure hospitalization, and is this benefit modified by sex, height, or QRS duration?
Meta-Analysis (n=3,496)
Yes
Does cardiac resynchronization therapy reduce all-cause mortality and heart failure hospitalization, and is this benefit modified by sex, height, or QRS duration?
The greater benefit of CRT observed in women is likely driven by their shorter height rather than sex itself, suggesting that QRS duration thresholds for CRT may need to be adjusted for patient height.
No takes yet. Share an insight, caveat, or question.
CRT benefit driven by height and QRS duration, not sex; challenges sex-specific thresholds and supports height-adjusted CRT selection criteria.
Linde et al. (2018) conducted a meta-analysis in Heart failure (n=3,496). Cardiac resynchronization therapy (CRT) vs. Control group was evaluated on All-cause mortality and the composite of all-cause mortality or first hospitalization for heart failure. Cardiac resynchronization therapy benefit was greater in shorter patients, with height and QRS duration (but not sex) acting as independent predictors of CRT benefit for the composite outcome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: